GlassScriptPhysician profile
Fadya Siso
NPI 1932854916
$14,543.10
in general payments reported to CMS, 2019-2025
23 companies · $4,951 in 2025
The $4,951 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $338 · 2023: $6,024 · 2024: $3,230 · 2025: $4,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Honoraria: $2,300 · Travel and Lodging: $1,035 · Education: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,416.29 |
| Honoraria | $2,300.00 |
| Travel and Lodging | $1,035.07 |
| Education | $453.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,939.74 | 2022-2023 | Krystexxa |
| Amgen INC. | $2,817.82 | 2022-2025 | Krystexxa, Enbrel, Tavneos |
| Abbvie INC. | $2,280.45 | 2023-2025 | |
| Janssen Biotech, INC. | $1,886.28 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $539.79 | 2022-2025 | |
| Ucb, INC. | $501.09 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $451.52 | 2022-2025 | Taltz, Zepbound |
| Genzyme Corporation | $429.02 | 2024-2025 | |
| Glaxosmithkline, LLC. | $389.67 | 2023-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $339.42 | 2023-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $176.38 | 2022-2025 | Saphnelo |
| Pfizer INC. | $156.93 | 2023-2025 | |
| Sandoz INC. | $136.67 | 2023-2025 | Hyrimoz, Jubbonti |
| Organon LLC | $90.90 | 2023-2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $79.04 | 2024-2025 | Idacio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $77.11 | 2024-2025 | Actemra, Gazyva |
| Aurinia Pharma U.S., INC. | $71.19 | 2023-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.85 | 2023-2024 | Cyltezo |
| Janssen Scientific Affairs, LLC | $48.10 | 2024 | Tremfya |
| Ani Pharmaceuticals, INC. | $26.25 | 2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $23.99 | 2023 | |
| Arcutis Biotherapeutics, INC. | $15.20 | 2023 | |
| Invivyd INC | $14.69 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadya Siso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.